Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015

Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06994CDB
  • |
  • Pages: 78
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Isis Pharmaceuticals, Inc. Snapshot 7

Isis Pharmaceuticals, Inc. Overview 7

Key Information 7

Key Facts 7

Isis Pharmaceuticals, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Isis Pharmaceuticals, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Isis Pharmaceuticals, Inc.-Pipeline Products Glance 17

Isis Pharmaceuticals, Inc.-Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Isis Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Isis Pharmaceuticals, Inc.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Isis Pharmaceuticals, Inc.-Drug Profiles 22


Product Description 22

Mechanism of Action 22

R&D Progress 22

nusinersen 23

Product Description 23

Mechanism of Action 23

R&D Progress 23


Product Description 25

Mechanism of Action 25

R&D Progress 25


Product Description 26

Mechanism of Action 26

R&D Progress 26


Product Description 28

Mechanism of Action 28

R&D Progress 28


Product Description 29

Mechanism of Action 29

R&D Progress 29


Product Description 30

Mechanism of Action 30

R&D Progress 30


Product Description 31

Mechanism of Action 31

R&D Progress 31

ISIS-DMPK-2.5 32

Product Description 32

Mechanism of Action 32

R&D Progress 32


Product Description 33

Mechanism of Action 33

R&D Progress 33


Product Description 34

Mechanism of Action 34

R&D Progress 34


Product Description 35

Mechanism of Action 35

R&D Progress 35


Product Description 36

Mechanism of Action 36

R&D Progress 36

Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis 38

Product Description 38

Mechanism of Action 38

R&D Progress 38


Product Description 39

Mechanism of Action 39

R&D Progress 39


Product Description 40

Mechanism of Action 40

R&D Progress 40


Product Description 41

Mechanism of Action 41

R&D Progress 41


Product Description 42

Mechanism of Action 42

R&D Progress 42


Product Description 43

Mechanism of Action 43

R&D Progress 43


Product Description 44

Mechanism of Action 44

R&D Progress 44


Product Description 45

Mechanism of Action 45

R&D Progress 45


Product Description 46

Mechanism of Action 46

R&D Progress 46


Product Description 47

Mechanism of Action 47

R&D Progress 47


Product Description 48

Mechanism of Action 48

R&D Progress 48

ISISRHO-2.5Rx 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Antisense Oligonucleotide 1 for Neurological and Neuromuscular Disorders 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Antisense Oligonucleotide 2 for Neurological and Neuromuscular Disorders 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Isis Pharmaceuticals, Inc.-Pipeline Analysis 53

Isis Pharmaceuticals, Inc.-Pipeline Products by Target 53

Isis Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 55

Isis Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 57

Isis Pharmaceuticals, Inc.-Recent Pipeline Updates 59

Isis Pharmaceuticals, Inc.-Dormant Projects 71

Isis Pharmaceuticals, Inc.-Discontinued Pipeline Products 72

Discontinued Pipeline Product Profiles 72

ISIS-104838 72

ISIS-113715 72

ISIS-14803 72

ISIS-2503 72

ISIS-5132 73



Isis Pharmaceuticals, Inc.-Company Statement 74

Isis Pharmaceuticals, Inc.-Locations And Subsidiaries 76

Head Office 76

Other Locations & Subsidiaries 76

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

Isis Pharmaceuticals, Inc., Key Information 7

Isis Pharmaceuticals, Inc., Key Facts 7

Isis Pharmaceuticals, Inc.-Pipeline by Indication, 2015 9

Isis Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Isis Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Isis Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Isis Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 14

Isis Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 15

Isis Pharmaceuticals, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Isis Pharmaceuticals, Inc.-Phase III, 2015 17

Isis Pharmaceuticals, Inc.-Phase II, 2015 18

Isis Pharmaceuticals, Inc.-Phase I, 2015 19

Isis Pharmaceuticals, Inc.-Preclinical, 2015 20

Isis Pharmaceuticals, Inc.-Discovery, 2015 21

Isis Pharmaceuticals, Inc.-Pipeline by Target, 2015 54

Isis Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 55

Isis Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 58

Isis Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 59

Isis Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 71

Isis Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 72

Isis Pharmaceuticals, Inc., Subsidiaries 76

List of Figures

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 9

Isis Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Isis Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Isis Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Isis Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 15

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 53

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 55

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Isis Pharmaceuticals, Inc.; Isis Pharmaceuticals, Inc. - Key Therapeutics; Isis Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Isis Pharmaceuticals, Inc. - News; Isis Pharmaceuticals, Inc. - Latest Updates; Isis Pharmaceuticals, Inc. - Pipeline; Isis Pharmaceuticals, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97335
Site License
USD 3000 INR 194670
Corporate User License
USD 4500 INR 292005



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]